DE SB176

Establish a Prescription Opioid Impact Fund in Delaware to finance opioid addiction prevention, treatment, residential programs, and emergency medical assistance including naloxone distribution.

Assess pharmaceutical manufacturers a Prescription Opioid Impact Fee of $0.01 per morphine milligram equivalent (MME) of prescription opioids dispensed in Delaware, calculated quarterly using Prescription Monitoring Program data.

Prohibit manufacturers from passing the fee cost to consumers and impose penalties of $100 per day or 10% of unpaid fees (whichever is greater), plus 1% monthly interest for non-payment.

Direct fund expenditures toward opioid addiction prevention and treatment, with no more than 25% used to reimburse State Medicaid costs and no more than 10% for administrative costs and Prescription Monitoring Program administration.

Require annual reporting to the Governor and General Assembly on fees collected, grant allocations, budget offsets, and number of individuals assisted; based on historical data, the fee would have generated approximately $9-11 million annually from 2015-2017.